NuVasive shareholders have approved the adoption of the company’s merger agreement with Globus Medical at a special meeting. Under the terms of the merger agreement, NuVasive shareholders will receive 0.75 of a share of Globus Medical Class A common stock for each share of NuVasive common stock owned at the closing of the transaction. Globus Medical will hold a separate special meeting of shareholders later today to vote on the issuance of Globus Medical shares to NuVasive shareholders in connection with the transaction.
NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced that at the special meeting of shareholders held earlier today, its shareholders voted to approve the adoption of the Company’s merger agreement with Globus Medical (NYSE: GMED). As previously announced, under the terms of the merger agreement, NuVasive shareholders will receive 0.75 of a share of Globus Medical Class A common stock for each share of NuVasive common stock owned at the closing of the transaction.
“We appreciate our shareholders’ strong support for NuVasive’s combination with Globus Medical,” said Chris Barry, chief executive officer of NuVasive. “We look forward to closing the transaction and realizing the significant benefits created by joining our more than 5,000 employees, geographic footprints, highly complementary innovations, customer bases and leading portfolios.”
Globus Medical is holding a separate special meeting of shareholders later today to vote on the issuance of Globus Medical shares to NuVasive shareholders in connection with the transaction.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
The final voting results of the NuVasive special meeting will be reported in a Form 8-K filed by NuVasive with the U.S. Securities and Exchange Commission.
Source: BioSpace